Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Breast 3Tumor-Agnostic 1Gynecologic 1CNS 1

Conditions

Urinary Bladder Neoplasms 1Stage I Prostate Adenocarcinoma 1Prostatic Neoplasms 1

Interventions

Docetaxel 229Radiotherapy 206Magnetic Resonance Spectroscopy 204Radiosurgery 176Gemcitabine 155pembrolizumab 151Nivolumab 147enzalutamide 140Prednisone 129Cisplatin 123Leuprolide 119Androgen Antagonists 117Abiraterone Acetate 114Sunitinib 106Specimen Handling 94Surveys and Questionnaires 91Goserelin 91bicalutamide 90Carboplatin 88Ipilimumab 82gallium 68 PSMA-11 80Blood Specimen Collection 78Everolimus 73apalutamide 72Radiation 71Standard of Care 68Biopsy 68acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 66Paclitaxel 64Cyclophosphamide 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Raloxifene Hydrochloride × Genitourinary × Clear all
NCT00710970 2022-01-24

Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment

Baylor College of Medicine

Phase 2 Completed
28 enrolled 8 charts
Genitourinary

Urinary Bladder Neoplasms

NCT03147196 2019-01-22

Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

Mayo Clinic

Phase 2 Withdrawn
Genitourinary

Stage I Prostate Adenocarcinoma

NCT01050842 2017-03-23

Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer

Mayo Clinic

Phase EARLY_PHASE1 Completed
18 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡